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Hypoxia-inducible genes have been linked to the aggressive phenotype of cancer. However, nearly all work on hypoxia-regulated
genes has been conducted in vitro on cell lines. We investigated the hypoxia transcriptome in primary human bladder cancer using
cDNA microarrays to compare genes induced by hypoxia in vitro in bladder cancer cell line EJ28 with genes upregulated in 39 bladder
tumour specimens (27 superficial and 12 invasive). We correlated array mRNA fold changes with carbonic anhydrase 9 (CA IX)
staining of tumours as a surrogate marker of hypoxia. Of 6000 genes, 32 were hypoxia inducible in vitro more than two-fold, five of
which were novel, including lactate transporter SLC16A3 and RNAse 4. Eight of 32 hypoxia-inducible genes in vitro were also
upregulated on the vivo array. Vascular endothelial growth factor mRNA was upregulated two-fold by hypoxia and 2–18-fold in 31
out of 39 tumours. Glucose transporter 1 was also upregulated on both arrays mRNA, and fold changes on the in vivo array
significantly correlated with CA IX staining of tumours (P¼0.008). However, insulin-like growth factor binding protein 3 mRNA was
the most strongly differentially expressed gene in both arrays and this confirmed its upregulation in urine of bladder cancer patients
(n¼157, Po0.01). This study defines genes suitable for an in vivo hypoxia ‘profile’, shows the heterogeneity of the hypoxia response
and describes new hypoxia-regulated genes.
British Journal of Cancer (2005) 93, 346–354. doi:10.1038/sj.bjc.6602666 www.bjcancer.com
Published online 19 July 2005
& 2005 Cancer Research UK
Keywords: microarray; hypoxia; carcinoma; bladder; HIF
                                               
Invasive bladder cancer has a mortality of approximately 50% and
new approaches to treatment include inhibiting angiogenesis or
targeting hypoxia cells. We and others have previously shown the
importance of angiogenic factors, such as vascular endothelial
growth factor (VEGF) measured in the urine or in the tumour,
in mediating bladder tumour angiogenesis (Chow et al, 1999;
Crew et al, 1999; Crew et al, 2000). We showed striking luminal
induction of VEGF in superficial bladder cancer (Turner et al,
2002). Vascular endothelial growth factor is a key angiogenic factor
and microvessel density as a measure of angiogenesis has been
shown to be highly associated with poor outcome in invasive
bladder cancer (Bochner et al, 1995). Vascular endothelial growth
factor is well recognised to be induced by hypoxia via hypoxia
inducible factor (HIF) and this suggests that genes induced by
hypoxia may be related to the aggressive phenotype. Indeed many
proteins upregulated by hypoxia play a role in invasion such as
urokinase plasminogen activator receptor, matrix metalloprotei-
nase 2 and cathepsin D. Direct clinical measurements of tumour
hypoxia with Eppendorf electrodes have shown it to be
independently related to prognosis, being associated with aggres-
sive local growth, metastasis and treatment failure whether from
radiotherapy or surgery, although these have not been done in
bladder cancer (Brizel et al, 1996; Hockel et al, 1996; Nordsmark
and Overgaard, 2000).
Apart from intratumoural hypoxia, genetic alterations also
upregulate HIF; loss of tumour suppressor genes such as PTEN
and activation of H-ras induce HIF, and these alterations are
common in bladder cancer.
Carbonic anhydrase IX (CA IX) is an extracellular enzyme
attached to the cell membrane that may generate the acidic pH of
tumours. We previously demonstrated the induction of CA IX
by hypoxia, its regulation by HIF and its correlation with tissue
hypoxia measured by oxygen electrodes in cervical cancer (Airley
et al, 2001). We also demonstrated that bladder cancers show
widespread staining for CA IX on the luminal surface and
perinecrotic areas (Turner et al, 2002). Clinical studies also
correlated the expression of CA IX with staining of bladder
tumours by pimonidazole (Wykoff et al, 2000). A recent study also
shows that bladder cancers expressing HIF have a poor prognosis
independent of stage and grade (Theodoropoulos et al, 2004).
Thus, hypoxia has a substantial role in bladder cancer biology.
We hypothesised that other hypoxia-regulated genes might
be significantly expressed in bladder cancer and relevant to its
biology. Since most analysis of genes induced by hypoxia has been
on cell lines in vitro, we analysed gene expression in primary
tumours vs comparator cell lines in normoxia. We considered
that genes upregulated in our tumour array would include those
induced by hypoxia since our comparator cell lines were in
normoxia.
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invasive bladder cancer cell line (EJ28) and compared the
expression of those genes with those upregulated in 39 primary
bladder tumours. This contrasts with other expression arrays
published for bladder cancer where a panel of four bladder cancer
cell lines (Sanchez-Carbayo et al, 2003) or four normal bladder
tissue samples (Dyrskjot et al, 2003) were used as reference. Using
the in vitro induced genes, we were able to define for each tumour
an in vivo hypoxia profile. We then stained 33 available tumours
from the expression study for CA IX as a surrogate marker of
hypoxia and compared the in vivo hypoxia gene profile with
tumour CA IX staining and necrosis. We also defined a hypoxia-
upregulated profile of genes from a single culture of normal
urothelial cells cultured from a strip of fresh human ureter. As
insulin-like growth factor binding protein 3 (IGFBP-3) was one
of the most induced and expressed genes in cancer and normal
urothelia in vitro and on the in vivo array, in a separate set of
157 urine samples from bladder cancer patients and controls we
analysed protein levels of IGFBP-3.
MATERIALS AND METHODS
Cell culture
Bladder cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with HEPES (EJ28, 253J 2T10) or RPMI 1%
(RT112) and supplemented with 1mM glutamine (GibcoBRL, UK),
0.002mgml
 1 puromycin and 10% fetal bovine serum (FBS)
(Globepharm, UK), in a humidified atmosphere of 5% CO2 at
37
oC. Human umbilical vein endothelial cells (HUVE cells) were
maintained in MCDB 131 (Gibco, Paisley, Scotland, UK). Human
umbilical vein endothelial cells were purchased from Clonetics
BioWhittaker (Wokingham, Berkshire, UK) and were cultured in
MCDB 131 medium (Invitrogen, Paisley, Scotland, UK) containing
20% fetal calf serum (Sigma-Aldrich), 100Uml
 1 penicillin,
100mgml
 1 streptomycin, 2mM glutamine, 5IUml
 1 heparin
and 50mgml
 1 endothelial cell growth supplement (Sigma, Dorset,
UK). Human umbilical vein endothelial cells were grown on plates
coated with 0.2% gelatine, and were used up to the 8th passage.
Cells were exposed to hypoxia by incubation in a humidified
atmosphere of 0.1% O2,5 %C O 2 and the remainder N2 in a NAPCO
7301 incubator (Precision Scientific, USA).
Normal urothelial culture
Samples of ureter were collected with informed consent and
approval from the Local Research Ethics Committee. A strip of
ice-cooled fresh normal human ureter from a patient undergoing
nephrectomy for renal cell cancer was placed in stripper medium
(0.1% EDTA, 10mM HEPES, Trasylol 500000IU in 500ml Hank’s
Balanced Salt Solution minus calcium and magnesium) for 6h
at 41C. The urothelial lining was scraped off, digested with
collagenase for 30min and plated on collagen-coated plates
(Becton Dickinson, NJ, USA) and cultured as previously described
(Cordon-Cardo et al, 1984; Dubeau and Jones, 1987; Schaafsma
et al, 1989). Cytospins were performed and cells stained for URO5
antibody, Cytokeratin 7 and Cytokeratin 20 confirming urothelium
as the cell of origin.
RNA extraction and storage
RNA was extracted using 7ml Trireagent (Sigma, UK) per 75cm
2
dish. Concentrations of RNA and purity were assessed on a UV
spectrometer. The integrity of the mRNA in this total RNA sample
was checked by running the RNA on a 1% agarose gel. Tumour
samples were collected with informed consent and approval from
the Local Research Ethics Committee.
Sanger microarrays, chips and analysis
Hver 1.2.1 cDNA microarrays were obtained from the Microarray
Consortium, Sanger Centre, Hinxton, Cambridge, UK. These
arrays contain 9932 spotted samples of cDNA originating from
the I.M.A.G.E. collections of the Human Genome mapping Project
and Research Genetics, Hinxton, UK, representing approximately
6000 human genes in total. A GSI Lumionics Scan Array 400
array reader with Scanarray and Quantarrays software was used
to analyse the slides. The analysed data were imported into
GeneSprings software (Silicon Genetics, USA). Data were
normalised internally by region on each chip (regional normal-
isation) to compensate for systematic variation over the surface of
the array. The mathematical Lowess correction was applied to
allow for nonlinear fluorescence characteristics of the dyes.
Generation of cell line reference RNA
To provide a controlled reference for each competitive hybridisa-
tion, a panel of 11 cell lines was harvested while in exponential
growth in culture (SK23, NCI-H1385, NCI-H69, IM-9, MCF-7,
OVCAR-3, MOLT-4, HEPG2, SW620, HT1376, W38). These cell
lines were selected according to previously published work at
Stanford (Perou et al, 2000) in order to reliably provide a constant
level of expression over the vast majority of genes on the array.
Generation of fluorescently labelled single-stranded cDNA
and competitive hybridisation of labelled single-stranded
cDNA
Between 25 and 50mg total RNA in 75% ethanol was mixed with
1ml of bacterial RNA cocktail (as internal control) and applied
to the microarray slide. This slide was placed in a hybridisation
chamber humidified with hybridisation buffer. Incubation oc-
curred at 471C for 12–24h. The slides were then placed in a slide
rack and washed in darkness in three different solutions contain-
ing SSC and 0.1% SDS on a tilting table for 1h. Slides were dried by
centrifugation.
Microarray analysis of genes upregulated by hypoxia
(0.1%) in cell line EJ28
We analysed gene expression in an aggressive bladder cancer cell
line EJ28 under normoxia and 16 and 24h hypoxia (0.1%). There
were four replicates at each time point grown in separate plates
compared with normoxic cells from the same passage harvested at
the same time.
Microarray analysis of 39 bladder cancers compared with
cancer cell line panel
The labelled cDNA from 39 bladder cancers was hybridised to the
chip with labelled cDNA from a panel of 11 cancer cell lines from
different types of cancer.
Real-time reverse transcription–polymerase chain
reaction (RT–PCR)
We used a commercial probe and primer sets (Applied Biosystems,
USA) for genes of interest. After RT of RNA (Invitrogen), cDNA
was diluted down to 0.5mgml
 1. The gene probe had an FAM
reporter dye. We chose Beta-2-microglobulin (B2M) as a control
gene as this is not known to be upregulated by hypoxia in the
literature, and was not upregulated by hypoxia in the cell line
on the array (data not shown). The relative Delta Ct technique of
real-time analysis was used looking at changes in cycle threshold
between three normoxic replicates and three hypoxic replicates.
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the difference between replicates.
Bladder tumour tissue microarray
A tissue array was made from paraffin blocks of 33 available gene
array cases. Whole sections of bladder cancer stained with
haematoxylin and eosin were reviewed under light microscopy
by a consultant histopathologist (IR) specialising in urological
cancer and one researcher (JO). Scoring of whole slides for
necrosis (negative¼none, positive¼either comedo or gross
intratumoral necrosis) was done blinded to the array results.
Tissue arrays are accepted forms of rapidly assessing antibodies on
a panel of tumours. The cores are significantly representative of
the whole block so long as at least two cores are used and regional
differences in staining are taken into account when selecting cores
(Camp et al, 2000; Nocito et al, 2001). Carbonic anhydrase IX
staining is known to be expressed in bladder cancer and to occur
more frequently around areas of necrosis (Wykoff et al, 2000). We
therefore selected two 1mm cores from representative areas of
tumour and if any necrotic areas existed another two perinecrotic
cores.
Carbonic anhydrase IX staining and scoring of tissue array
The tissue array was stained with the CA IX antibody M75 as
described (Wykoff et al, 2000). Scoring was as described (Turner
et al, 2002): a score of 0–3 (0¼no staining, 3¼strong staining in
450% of the core) was given based on intensity and area of
membrane staining of tumour cells. Scores from more than one
core were summed. Carbonic anhydrase IX positivity was defined
as a score 41.5, which was the median score. Correlation of
tumour CA IX staining scores with gene fold changes for all eight
genes individually and summed was tested using linear regression.
Goodness of fit was calculated as r
2 and Po0.05 cutoff taken for a
significantly nonzero slope.
Urine collection
Urine was collected with informed consent fresh from patients
with histologically confirmed bladder cancer, an average of 1 week
before operation as described (Crew et al, 1999). There were 69
superficial cancers, 19 invasive, four carcinoma in situ, 34 patients
who had previously had bladder cancer resected and were now
clear, and 29 controls. Of 29 controls, 12 were 43–80 years old
who had full investigations for haematuria with no bladder cancer
found; the remaining 17 were medical student volunteers aged
18–30 years with no blood in the urine on dipstix. Urine levels of
IGFBP3 were compared using a two-tailed t-test, nonparametric
with significance cutoff Po0.05.
RESULTS
Array results in bladder cancer cell line
We minimised false positive genes by initially including those with
raw absolute values of 41000. Of 6000 genes analysed, 32 (0.53%)
were upregulated by hypoxia in the cell line EJ28 more than
two-fold in at least six of eight replicates (four at 16h and four at
24h) (Table 1). Adrenomedullin (ADM), upregulated 17-fold, and
IGFBP-3, upregulated 12-fold, were the most upregulated genes,
with VEGF less at 2.5-fold. Adrenomedullin is known to have a
range of effects on vasculature including vasodilatation and
angiogenesis (Nikitenko et al, 2002). Insulin-like growth factor
binding protein 3 is the major binding protein for insulin-like
growth factors in the blood and also has IGF-independent
apoptotic effects. Nearly all genes either increased or retained
the upregulation found at 16h and at 24h. These genes divided
into functional groups typical of hypoxia-induced genes (Harris,
2002) (Table 1). Several genes not previously known to be
upregulated by hypoxia included Ribonuclease 4 RNAse4 3.1-fold,
monocarboxylate transporter family member 4 (SLC16A3 also
called MCT4), Preferentially expressed antigen of melanoma
PRAME 4.9-fold and Importin Beta 3 4.1-fold. The protein kinase
C substrate MARCKS also appeared upregulated 2.2-fold at 16h.
Validation of hypoxia-upregulated genes by RT–PCR in
EJ28, bladder cancer cell lines and primary urothelial and
endothelial cell culture
Six genes were analysed: IGFBP-3, RNAse4, SLC16A3, MARCKS,
using two controls B2M and Peroxiredoxin. Two novel genes not
previously known to be upregulated by hypoxia in vitro were
RNAse 4 and SLC16A3 (a lactate transporter chosen for its
potential relevance to hypoxia). Both were confirmed to be
upregulated in a panel of cell lines (Table 2). SLC16A3 RNA was
also upregulated by hypoxia in HUVE cells but not in cultured
normal urothelium. RNAse 4 like IGFBP-3 was upregulated by
hypoxia in the cell lines and normal urothelial cells. The control
gene B2M showed no significant change by comparison. Nor did
a second control gene Peroxiredoxin selected from the tumour
array by its lack of fold change (data not shown). MARCKS was
upregulated by hypoxia 2.1-fold on the in vitro array. However,
MARCKS upregulation in the cell line panel was not confirmed.
Array results in primary bladder tumours
Of 6000 genes on the tumour arrays, 70 (1.2%) were upregulated
more than two-fold in over 30 tumours. We compared the results
for hypoxia-regulated genes from the cell line with the bladder
tumour array (Figure 1). Of the 32 genes upregulated by hypoxia
in vitro, eight genes were upregulated more than two-fold with
raw signal intensity 41000 in more than five of the 39 tumours.
Vascular endothelial growth factor, which is known to be
expressed in bladder cancer, was upregulated 2.5-fold by hypoxia
and 2–18-fold in 31 out of 39 tumours making it the second most
frequently upregulated hypoxia-inducible gene. The most highly
and frequently upregulated gene in both arrays, however, was the
mRNA IGFBP-3. This was upregulated up to 12-fold by hypoxia
in vitro and from 2 to 100-fold in 33/39 tumours compared to the
cell line panel. The other six genes with more than two-fold
upregulation in more than five tumours arrayed were CCNG2 in 30
tumours, NDRG1 in 18 tumours, PFKFB3 in 17 tumours, RNAse4
in 10 tumours, Adrenomedullin (ADM) in eight tumours and
Glucose transporter 1 (GLUT-1) in six tumours. The cumulative
fold changes for all eight genes are plotted for each tumour
(Figure 2). It can be seen that IGFBP-3 is more upregulated than
the others in individual tumours.
Of 32 genes upregulated by hypoxia in vitro, 24 were
downregulated on the in vivo array (definition of downregulated
– more than 0.5-fold lower in more than five tumour samples). The
most downregulated gene in vivo was lactate dehydrogenase.
Genes that were most induced in vitro were more likely to be
upregulated in vivo; six of the 10 most hypoxia-induced genes on
the in vitro array were upregulated in the in vivo array vs only one
of the remaining genes (P¼0.02 Fisher’s exact test six out of 10 vs
one out of 13).
SLC16A3 was strongly regulated in tumour cell lines and HUVE
cells in vitro and although signal was low in tumours it was
upregulated more than two-fold in seven tumours. A paired t-test
of the raw data showed significant upregulation (mean control
signal 520, mean raw signal 690, ratio 1.3, P¼0.0003). To see if this
occurred in cell lines from other tumour types, two breast cancer
cell lines were studied (T47D, MDA 468) and also showed
induction (Table 2).
Hypoxia-induced genes in bladder cancer
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sTable 1 Mean fold changes of all 32 genes upregulated more than two-fold by hypoxia (0.1%) at 16 and 24h in cell line EJ28
Fold change at hypoxia
No. 16h 24h Gene Functional group
Known to be hypoxia upregulated in other cell lines
1 3.4 17 Adrenomedullin (ADM)* Angiogenesis
2 2.6 12.1 Insulin-like growth factor binding protein 3 (IGFBP-3)* Apoptosis
3 2.9 8.2 n-myc downstream regulated protein 1 (NDRG1)* Cell cycle
4 5.3 6.6 NIP3 Proapoptotic
5 2.7 4.7 Induclble 6-phosphofructo-2-klnase (PFKFB3)* Glucose metabolism
6 2.4 4.7 Lysyl hydroxylase (PLOD2) Tissue remodelling
7 2.2 4.4 MAX interacting protein 1 Transcription factor
8 3.1 4.2 Glucose transporter 1 (GLUT 1)* Glucose metabolism
9 2.3 3.9 1,4-Alpha glucan branching enzyme Glucose metabolism
10 2.2 3.8 Cyclin G2* Cell cycle
11 2.5 3.7 Proline-4-hydroxylase (P4HA1) Oxygen sensing
12 3.2 3.2 Adenylate kinase 4 Energy metabolism
13 2.9 3.1 Aldolase C Glucose metabolism
14 1.9 3 Prolyl-4-hydroxylase alpha subunlt Oxygen sensing
15 1.8 2.6 Haem oxygenase 1 Haem degradation
16 2.5 2.5 EGL9 homologue 1 Oxygen sensing
17 2.1 2.5 Testis-specific lactate dehydrogenase Acid base
18 1.9 2.5 VEGF* Angiogenesis
19 2.4 2.5 Adenylate kinase 3 Energy metabolism
20 1.7 2.4 Dual specificity phosphatase 1 (DUSP1/CL100/MKP1) Cell signalling
21 1.7 2.1 DEC 1 Differentiation
22 2.6 2.1 Glucose-6-phosphate isomerase Glucose metabolism
23 2.1 2.1 Fructose-bisphosphate aldolase A Glucose metabolism
Not previously known to be hypoxia regulable
24 2.8 8.2 Solute carrier family 16 member 3 (SLC16A3) Acid base
25 4.5 4.9 Preferentially expressed antigen of melanoma (PRAME) Antigen
26 2.8 4.1 Importin Beta 3 Nuclear pore protein
27 1.9 3.1 RNAse4* Antimicrobial?
28 2.2 2.9 Protooncogene ABL1 Cell cycle
ESTs
29 3 3.9 50378_A EST
30 3.2 3.3 50022_A EST
31 3.5 3.3 31564_B EST
32 2.1 2.4 21875 A EST
Microarray result of eight biological replicates; genes had to be upregulated more than two-fold with high raw signal intensity (41000 units) in more than six of eight replicates to
avoid false positives and be included in this list. Eight asterisked genes (*) were also significantly upregulated on the in vivo array. EST¼expressed sequence tag.
Table 2 Fold changes of IGFBP-3, RNAse4 and SLC16A3 by hypoxia (0.1%) in bladder cancer cell lines, normal cultured human urothelia and HUVE cells
analysed by real-time RT–PCR
Cell type Hours of hypoxia IGFBP-3 Control RNAse4 Control SLC16A3 Control
Bladder cell line EJ28 16 3.6 1 5.35 1
EJ28 24 5.5 1.2 6.5 1 6.4 1
2T10 16 14.5 1.3 3.4 1 5.5 1
253J 16 3.4 1.1 3.9 1.1 2.1 1.1
RT112 16 38 1.4 3.8 1.3 3.8 1.4
Normal urothelium 16 4.6 1.1 3.7 1  1.3 1
Endothelial cells HUVEC 16 7  1.4 64 1.6
Three replicates of each experiment were performed and if replicates were more than 0.5 cycles different, the result was not accepted. The control gene Beta-2-microglobulin in
each experiment did not differ significantly from normoxia to hypoxia but any trend to change of the control gene is demonstrated by minimal fold changes (range  1.4 to 1.6).
Fold change calculated on the basis of 2 to the power of the change in cycle number at a set threshold. Differences in gene of interest in normoxia and hypoxia all showed a
significant difference in average cycle threshold (Po0.01) unless indicated. Negative values indicate downregulation.
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To correlate the in vivo transcriptome of these tumours with
tumour hypoxia, we scored paraffin sections of the tumours using
CA IX stain as a marker of hypoxia. We also scored tumours for
the presence of intratumoural necrosis seen with haematoxylin and
eosin stain. A total of 32 tumours were available for both scores, 11
invasive and 21 superficial. Necrosis was present in five invasives
and two superficials. CA IX scoring was positive in three invasive
cancers and 13 superficial tumours. A total of three necrotic
tumours were also CA IX positive. GLUT-1 fold changes correlated
with CA IX scores (P¼0.008 r
2¼0.21, Figure 3), and were
significantly higher in CA IX-positive tumours (means 0.9 vs 1.8
P¼0.03 two-tailed t-test variances not assumed to be equal).
Urine IGFBP-3 protein is raised in bladder cancer
Insulin-like growth factor binding protein 3 at the transcript level
was upregulated higher and more frequently than VEGF in both
in vitro and in vivo arrays. We therefore measured levels of
IGFBP-3 protein in the urine (Figure 4). Urine from 157 bladder
cancer patients and controls was collected prospectively and
IGFBP-3 levels were measured by ELISA. There was a significant
increase in urinary IGFBP-3 concentration from control/clear
groups to superficial cancers to invasive cancers, Po0.01 for
superficial vs control/clear, Po0.01 for invasive vs control/clear
(IGFBP-3ngml
 1 mean (standard deviation); controls 15.2ngml
 1
(7.55); clears 14.6ngml
 1 (8.1); superficial 27.7ngml
 1 (29);
invasive 55.1ngml
 1 (40)). After correction for urinary creatinine,
significance (Po0.01) was retained for invasive tumours, but not
for the superficial group. There were 15 stage T1G3 tumours in the
superficial group. There was no significant difference between
levels in the urine of T1G3 tumours and other superficial tumours
or with the invasive group. If a single exceptionally high (44
standard deviations) level in the superficial group is excluded, the
mean corrected levels of urine IGFBP-3 increase with stage and
grade: superficial (T1G2 or lower) 351ngmmol
 1 Cr (creatinine);
T1G3 479ngmmol
 1 Cr; invasive 733ngmmol
 1 Cr.
One of the anonymously taken medical student controls had a
level of IGFBP-3 five standard deviations higher than the rest of
this group. Despite this, the significant difference between this
group and the bladder cancer group held. All medical student
control urines dipped negative for blood so an undiagnosed cancer
is unlikely in such a young person. The likely explanation is an
exercise-induced rise in IGFBP-3 (Manetta et al, 2002).
DISCUSSION
The in vitro analysis of hypoxia-induced genes showed several
genes already well recognised to be induced by hypoxia, and also
other genes likely to be of functional importance in the response to
hypoxia.
SLC16A3 is a new hypoxia-regulated gene. This occurred
particularly in HUVEC cells, and also in bladder and breast cell
lines, but not in cultured normal urothelium. It is a member of
the proton-linked transmembrane monocarboxylate transporter
(MCT) family with high affinity for lactate (Halestrap and Price,
1999). It is particularly high in the white skeletal muscle, white
blood cells and cell lines, suggesting that it may be of particular
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Figure 1 Graphic representation of array results of in vivo hypoxia gene
expression in bladder cancers, for all genes induced by hypoxia in vitro (as
listed in Table 1): in order of Genespring ‘Interest’ function that places the
most statistically trustworthy and greatest fold changes towards the top of
the list. Some genes have more than one result as they were represented
by more than one spot on the array. 39 columns¼39 tumour samples.
Samples 1 (on left) to 26¼superficial, samples 27–39¼muscle invasive.
One row¼one gene as labelled. Tumour cDNA was competitively
hybridised against a panel of 11 cancer cell lines. Red¼two-fold or
more upregulation, green¼downregulation, brown equals no change.
Brightness¼statistical trust.
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production.
The upregulation of RNAse4 by hypoxia is also novel. The
human enzyme is secreted into plasma and the gene (Rosenberg
and Dyer, 1995) shares various identical 50-untranslated regions on
its mRNA with the angiogenic factor angiogenin, suggesting that
expression of the proteins is under similar control, with obvious
implications for their biological activities. Angiogenin is upregu-
lated by hypoxia in cell lines and is raised in the blood and
tumours of patients with bladder cancer (Miyake et al, 1999).
On the tumour array, 70 of 6000 (1.2%) genes were upregulated
more than two-fold in over 30 tumours. Three of these 70 genes
(4.3%) were hypoxia inducible on the in vitro array (IGFBP-3,
VEGF, CCNG2). Since only 32 of 6000 (0.53%) genes on the in vitro
array were upregulated by hypoxia, hypoxia-induced genes are
eight times over-represented in the group of genes most
upregulated on the tumour array (Po 0.01 w
2 test). However, of
the 32 genes upregulated in vitro, only eight were upregulated in
the tumour samples.
In contrast, 24 were downregulated more than 0.5-fold in more
than five tumour samples (green) in vivo (Figure 1). There are
several possible reasons for this. The in vivo array, comparing as it
does tumour samples to a panel of cell lines may be highlighting
the more complex influences on gene expression present in the
three-dimensional environment. Three-dimensional geometry of
in vitro cell growth alone has been shown to have dramatic
influences on biological function and gene expression profile
(Dangles et al, 2002).
The apparent downregulation of NIP3, Aldolase C, PLOD2 and
other hypoxia-inducible genes on the in vivo array in all tumour
samples, even in tumours where hypoxia and necrosis were
present, may represent a relative basal upregulation of these genes
in the monolayer cell culture panel. The subset of known hypoxia-
inducible genes that were clearly upregulated in vitro but not in
vivo in general was less inducible. The combination of pure in vitro
cancer cell populations with basal upregulation of the pathways,
possibly via oncogene pathways know to regulate HIF, is probably
sufficient to explain this.
Since we used a widely described cell line panel as a control, this
has some implications for interpretation of such arrays. In our
study we were specifically investigating a defined pathway, but if
we used the tumour array results alone without considering genes
in the same pathway, this effect may not have been noted.
We might have expected all eight genes significantly upregulated
by hypoxia in vitro and in vivo to correlate with tumour scores
of hypoxia and necrosis in vivo. Glucose transporter 1 (GLUT1)
transcription fold changes on the in vivo array showed a significant
correlation with the immunohistochemical CA IX score as a
surrogate marker of hypoxia. Glucose transporter and ADM also
showed significant correlation with each other. Glucose transporter
1 protein immunohistochemistry has previously been shown to
correlate with CA IX staining in cervical cancer and, like CA IX,
it has been shown to be a marker of tumour hypoxia (Airley et al,
2001, 2003). The correlation here shows that the same is also likely
to be true for bladder cancer. Adrenomedullin, a secreted protein,
may also prove to be useful as a marker of hypoxic tumours in
the urine. The other genes did not correlate with tumour hypoxia
and necrosis scores and were upregulated in many tumours. The
result highlights the complexity and heterogeneity of the hypoxia
response, suggesting that the final pattern may be individual.
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Figure 2 Tumour samples categorised by the fold upregulation of the eight genes upregulated by hypoxia in the cell line and upregulated more than two-
fold in more than five tumour samples on the in vivo array. Insulin-like growth factor binding protein 3 makes the largest fold contribution and is upregulated
more than two-fold in the majority of samples.
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oncogenic changes specific to bladder cancer, but which are not
found in the majority of the cell line panel, may also contribute to
their expression. Examples of genes that are mutated in bladder
cancer include p53, PTEN and H-ras, which upregulate HIF
(Krishnamachary et al, 2003). The HER2 oncogene is known to
upregulate IGFBP-3, and was upregulated on the in vivo array
more than two-fold in 22 of 39 tumour samples.
The gene most frequently and proportionally upregulated was
IGFBP-3, which is known to be hypoxia inducible in a number
of cell lines. We show that this is also true of bladder cell lines
and is not specific to cancer, with upregulation in human
cultured urothelium (4.6-fold) and HUVE cells (7-fold). Insulin-
like growth factor binding protein 3 may act as a direct apoptotic
response to hypoxia, and this implies that there are major
selective mechanisms in vivo to overcome this pathway and
suggests that antagonising the IGF1 receptor could have high
selectivity in cancer, with endogenous IGFBP-3 synergising with
such inhibition.
In contrast to its extracellular IGF-binding role, an intracellular
role of IGFBP-3 has been described (Schedlich et al, 2003), with
phosphorylation increasing nuclear import of IGFBP-3, with
release of IGF. The mechanism involves interaction with Importin
Beta (Schedlich et al, 2003), a gene not previously recognised to be
regulated by hypoxia, which was induced by hypoxia in our study
(4.1-fold) in vitro. Thus, induction of IGFBP3 may have a more
complex role then previously reported.
The finding of raised IGFBP-3 in the urine of bladder cancer
patients has not been previously noted. In vitro experiments on
cell growth and IGFBP-3 make it likely that the levels of IGFBP-3
seen here in urine are of clinical significance. Levels as low as
10ngml
 1 and more commonly 30–50ngml
 1 have been shown
to have inhibitory effects on growth of neoplastic cells in vitro
(Martin and Baxter, 1999; Ewton et al, 2002). It is often assumed to
be growth inhibitory, but IGFBP-3 has a stimulatory effect on
the growth of smooth muscle bladder cells in vitro (Weinzimer
et al, 2001). It must also be noted that the ELISA measures both
proteolysed fragments and intact IGFBP-3 (Diamandi et al, 2000).
The rise we measured may reflect increased proteolysis of
IGFBP-3 that would make more IGF available to the tumour.
However, the array data suggest at least that direct upregulation of
mRNA levels of IGFBP-3 occur, with or without increased
proteolysis.
Cyclin G2 is known to be regulated by the VHL/hypoxia pathway
(Wykoff et al, 2000). It is a negative regulator of the cell cycle with
peak expression in S phase and it stimulates apoptosis (Bennin
et al, 2002). Cyclin G2 RNA levels were shown in another array to
be expressed at a lower level in stage T2 bladder tumours than in
Ta (Dyrskjot et al, 2003). Cyclin G2 was also upregulated in Ta
tumours compared to normal tissue. This contrasts with the result
on the tumour array here, where there was no significant
difference in Cyclin G2 fold change from Ta to T2 tumours. This
difference may be because our array used a panel of cell lines as
reference rather than normal bladder tissue.
Overall, these results show that there is concordance in vivo
for a subset of hypoxia-induced genes (ADM, GLUT1 and CA IX
protein), which may provide a hypoxia signature for analysis of
gene array data. Hoskin et al (2003) showed that GLUT1 and
CAIX expressions in invasive bladder cancer were correlated
with hypoxia and outcome of radiation therapy. However, there
is also an individual pattern of expression for each patient.
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sHypoxia-regulated genes are disproportionately upregulated in
primary bladder cancer. The induction of putative proapoptotic,
cell cycle arrest pathways commonly occurs (IGFBP-3 and CCNG2)
and may act to select apoptosis resistance pathways in vivo,
and therefore a more comprehensive analysis in clinical trials may
help refine predictions of those who would benefit from
modulation of hypoxia and the variability in outcome even when
using GLUT1.
ACKNOWLEDGEMENTS
We thank the Royal College of Surgeons for funding the first year of
this project and Oxford Health Services Research Committee for
further funding in the second year, and Margaret Knowles in Leeds
for the normal urothelial cell culture protocol. This research was
supported by Cancer Research UK, Royal College of Surgeons of
England and Oxford Regional Health Services Research Committee.
REFERENCES
Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A,
Hunter R, Stratford I, West C (2001) Glucose transporter glut-1
expression correlates with tumor hypoxia and predicts metastasis-free
survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928–934
Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD,
West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of
hypoxia in carcinoma of the cervix: relationship to pimonidazole
binding. Int J Cancer 104: 85–91
Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L,
DePaoli-Roach AA, Horne MC (2002) Cyclin G2 associates with protein
phosphatase 2A catalytic and regulatory B’ subunits in active complexes
and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol
Chem 277: 27449–27467
Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG,
Nichols PW (1995) Angiogenesis in bladder cancer: relationship
between microvessel density and tumor prognosis. J Natl Cancer Inst
87: 1603–1612
Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR,
Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of
distant metastases in human soft tissue sarcoma. Cancer Res 56: 941–943
Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray
technology in breast carcinoma. Lab Invest 80: 1943–1949
Chow NH, Liu HS, Chan SH, Cheng HL, Tzai TS (1999) Expression of
vascular endothelial growth factor in primary superficial bladder cancer.
Anticancer Res 19: 4593–4597
Cordon-Cardo C, Bander NH, Fradet Y, Finstad CL, Whitmore WF, Lloyd
KO, Oettgen HF, Melamed MR, Old LJ (1984) Immunoanatomic
dissection of the human urinary tract by monoclonal antibodies.
J Histochem Cytochem 32: 1035–1040
Crew J, Fuggle S, Bicknell R, Cranston D, Benedetti AD, Harris A (2000)
Eukaryotic initiation factor-4E in superficial and muscle invasive bladder
cancer and its correlation with vascular endothelial growth factor
expression and tumor progression. Br J Cancer 82: 161–166
Crew JP, O’Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL (1999)
Urinary vascular endothelial growth factor and its correlation with
bladder cancer recurrence rates. J Urol 161: 799–804
Dangles V, Lazar V, Validire P, Richon S, Wertheimer M, Laville V, Janneau
JL, Barrois M, Bovin C, Poynard T, Vallancien G, Bellet D (2002) Gene
expression profiles of bladder cancers: evidence for a striking effect of in
vitro cell models on gene patterns. Br J Cancer 86: 1283–1289
Diamandi A, Mistry J, Krishna RG, Khosravi J (2000) Immunoassay of
insulin-like growth factor-binding protein-3 (IGFBP-3): new means to
quantifying IGFBP-3 proteolysis. J Clin Endocrinol Metab 85: 2327–2333
Dubeau L, Jones PA (1987) Growth of normal and neoplastic urothelium
and response to epidermal growth factor in a defined serum-free
medium. Cancer Res 47: 2107–2112
Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-
Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of
bladder carcinoma using microarrays. Nat Genet 33: 90–96
Ewton DZ, Kansra S, Lim S, Friedman E (2002) Insulin-like growth factor-I
has a biphasic effect on colon carcinoma cells through transient
inactivation of forkhead1, initially mitogenic, then mediating growth
arrest and differentiation. Int J Cancer 98: 665–673
Halestrap AP, Price NT (1999) The proton-linked monocarboxylate
transporter (MCT) family: structure, function and regulation. Biochem
J 343(Part 2): 281–299
Harris AL (2002) Hypoxia – a key regulatory factor in tumour growth. Nat
Rev Cancer 2: 38–47
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996)
Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res 56: 4509–4515
Hoskin PJ, Sibtain A, Daley FM, Wilson GD (2003) GLUT1 and CAIX as
intrinsic markers of hypoxia in bladder cancer: relationship with
vascularity and proliferation as predictors of outcome of ARCON. Br J
Cancer 89: 1290–1297
Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G,
Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL (2003) Regulation of
colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res
63: 1138–1143
Manetta J, Brun JF, Maimoun L, Callis A, Prefaut C, Mercier J (2002) Effect
of training on the GH/IGF-I axis during exercise in middle-aged men:
relationship to glucose homeostasis. Am J Physiol Endocrinol Metab 283:
E929–E936
Martin JL, Baxter RC (1999) Oncogenic ras causes resistance to the growth
inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in
breast cancer cells. J Biol Chem 274: 16407–16411
Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999)
Increased angiogenin expression in the tumor tissue and serum of
urothelial carcinoma patients is related to disease progression and
recurrence. Cancer 86: 316–324
Nikitenko LL, Smith DM, Hague S, Wilson CR, Bicknell R, Rees MC (2002)
Adrenomedullin and the microvasculature. Trends Pharmacol Sci 23:
101–103
Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U,
Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D,
Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M,
Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P,
Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G
(2001) Microarrays of bladder cancer tissue are highly representative
of proliferation index and histological grade. J Pathol 194:
349–357
Nordsmark M, Overgaard J (2000) A confirmatory prognostic study on
oxygenation status and loco-regional control in advanced head and neck
squamous cell carcinoma treated by radiation therapy. Radiother Oncol
57: 39–43
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack
JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO,
Botstein D (2000) Molecular portraits of human breast tumours. Nature
406: 747–752
Rosenberg HF, Dyer KD (1995) Human ribonuclease 4 (RNase 4):
coding sequence, chromosomal localization and identification of two
distinct transcripts in human somatic tissues. Nucleic Acids Res 23:
4290–4295
Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin
TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C (2003) Gene
discovery in bladder cancer progression using cDNA microarrays. Am J
Pathol 163: 505–516
Schaafsma HE, Ramaekers FC, van Muijen GN, Ooms EC, Ruiter DJ (1989)
Distribution of cytokeratin polypeptides in epithelia of the adult human
urinary tract. Histochemistry 91: 151–159
Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC (2003)
Phosphorylation of insulin-like growth factor binding protein-3
by deoxyribonucleic acid-dependent protein kinase reduces ligand
binding and enhances nuclear accumulation. Endocrinology 144:
1984–1993
Theodoropoulos VE, Lazaris A, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I,
Manikas K, Kastriotis I (2004) Hypoxia-inducible factor 1 alpha
expression correlates with angiogenesis and unfavorable prognosis in
bladder cancer. Eur Urol 46: 200–208
Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J,
Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes
Hypoxia-induced genes in bladder cancer
JJ Ord et al
353
British Journal of Cancer (2005) 93(3), 346–354 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sVEGF and CA9 are differentially regulated in superficial vs invasive
bladder cancer. Br J Cancer 86: 1276–1282
Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P
(2001) Transferrin is an insulin-like growth factor-binding protein-3
binding protein. J Clin Endocrinol Metab 86: 1806–1813
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J,
Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH,
Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible
expression of tumor-associated carbonic anhydrases. Cancer Res 60:
7075–7083
Hypoxia-induced genes in bladder cancer
JJ Ord et al
354
British Journal of Cancer (2005) 93(3), 346–354 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s